You are here:

rivaroxaban (Xarelto)

Advice

following a full submission

rivaroxaban (Xarelto®) is not recommended for use within NHS Scotland.

Indication under review: rivaroxaban co-administered with aspirin alone or with aspirin plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.

Rivaroxaban in addition to standard care significantly reduced the occurrence of the primary composite endpoint: death from cardiovascular causes, myocardial infarction, or stroke, compared to standard care alone.

The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Drug Details

Drug Name: rivaroxaban (Xarelto)
SMC Drug ID: 1062/15
Manufacturer: Bayer plc/Bayer Schering Pharma
Indication: Rivaroxaban co-administered with aspirin alone or with aspirin plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.
BNF Category:
Sub Category: 2.8 Anticoagulants and protamine
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 13 July 2015

Back